ReviewAnnals of translational medicine2021
Inhaled pulmonary vasodilators: a narrative review.
Review in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06702553 (Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Phase III, Double-Blind, Multicenter, Randomized Controlled Trial (Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass, the NORISC Trial)
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- A randomised controlled trial on roles of prostaglandin E1 nebulization among patients undergoing one lung ventilation.BMC pulmonary medicine · 2022Trial
- Inhaled pulmonary vasodilators in pulmonary hypertension: Perioperative use and clinical considerations.JHLT open · 2026Article
- Ventilator Weaning Failure Induced by Oral Beraprost in a Patient after Femoral Endarterectomy: A Case Report.Annals of vascular diseases · 2026Article
- Inhaled nitric oxide therapy is effective in improving right ventricular function in patients receiving ECPELLA support.General thoracic and cardiovascular surgery · 2026Article
- Article
- The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus.Journal of diabetes science and technology · 2025Article
- Inhaled nitric oxide clinical confusions: population types, duration, and responsiveness.Critical care (London, England) · 2024Article
- Novel inhaled pulmonary vasodilators in adult cardiac surgery: a scoping review.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2024Article
- A Comparative Investigation of the Pulmonary Vasodilating Effects of Inhaled NO Gas Therapy and Inhalation of a New Drug Formulation Containing a NO Donor Metabolite (SIN-1A).International journal of molecular sciences · 2024Article
- Perioperative management of the vulnerable and failing right ventricle.Perioperative medicine (London, England) · 2024Review
- Low-frequency ultrasound for pulmonary hypertension therapy.Respiratory research · 2024Article
- Nebuliser therapy in critical care: The past, present and future.Journal of the Intensive Care Society · 2024Review
- Inhaled Pulmonary Vasodilators for the Treatment of Right Ventricular Failure in Cardio-Thoracic Surgery: Is One Better than the Others?Journal of clinical medicine · 2024Review
- Management Considerations for Pulmonary Arterial Hypertension Pharmacotherapy in the Intensive Care Unit.Pharmacy (Basel, Switzerland) · 2023Review
- Article
- Nitric Oxide in Cardiac Surgery: A Review Article.Biomedicines · 2023Review
- Effects of Iloprost on Arterial Oxygenation and Lung Mechanics during One-Lung Ventilation in Supine-Positioned Patients: A Randomized Controlled Study.Journal of personalized medicine · 2022Article
- Initiation of Inhaled Nitric Oxide by an Air Transport Team in Adult Coronavirus Disease 2019 Respiratory Failure.Air medical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is a severe disease that affects people of all ages. It can occur as an idiopathic disorder at birth or as part of a variety of cardiovascular and pulmonary disorders. Inhaled pulmonary vasodilators (IPV) can reduce pulmonary vascular resistance (PVR) and improve RV function with minimal systemic effects. IPV includes inhaled nitric oxide (iNO), inhaled aerosolized prostacyclin, or analogs, including epoprostenol, iloprost, treprostinil, and other vasodilators. In addition to pulmonary vasodilating effects, IPV can also be used to improve oxygenation, reduce inflammation, and protect cell. Off-label use of IPV is common in daily clinical practice. However, evidence supporting the inhalational administration of these medications is limited, inconclusive, and controversial regarding their safety and efficacy. We conducted a search for relevant papers published up to May 2020 in four databases: PubMed, Google Scholar, EMBASE and Web of Science. This review demonstrates that the clinical using and updated evidence of IPV. iNO is widely used in neonates, pediatrics, and adults with different cardiopulmonary diseases. The limitations of iNO include high cost, flat dose-response, risk of significant rebound PH after withdrawal, and the requirement of complex technology for monitoring. The literature suggests that inhaled aerosolized epoprostenol, iloprost, treprostinil and others such as milrinone and levosimendan may be similar to iNO. More research of IPV is needed to determine acceptable inclusion criteria, long-term outcomes, and management strategies including time, dose, and duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.